|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF644 |
Gene summary for ZNF644 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF644 | Gene ID | 84146 |
| Gene name | zinc finger protein 644 | |
| Gene Alias | BM-005 | |
| Cytomap | 1p22.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9H582 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84146 | ZNF644 | CA_HPV_1 | Human | Cervix | CC | 1.42e-02 | -1.57e-02 | 0.0264 |
| 84146 | ZNF644 | CCI_1 | Human | Cervix | CC | 3.07e-05 | 8.75e-01 | 0.528 |
| 84146 | ZNF644 | CCI_2 | Human | Cervix | CC | 3.23e-13 | 1.23e+00 | 0.5249 |
| 84146 | ZNF644 | CCI_3 | Human | Cervix | CC | 2.13e-09 | 1.03e+00 | 0.516 |
| 84146 | ZNF644 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.11e-31 | -9.07e-01 | 0.0155 |
| 84146 | ZNF644 | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.85e-17 | -8.23e-01 | -0.1808 |
| 84146 | ZNF644 | HTA11_2951_2000001011 | Human | Colorectum | AD | 1.88e-03 | -8.31e-01 | 0.0216 |
| 84146 | ZNF644 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.10e-03 | -5.41e-01 | -0.0811 |
| 84146 | ZNF644 | HTA11_78_2000001011 | Human | Colorectum | AD | 3.72e-07 | -6.06e-01 | -0.1088 |
| 84146 | ZNF644 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.44e-16 | -8.72e-01 | -0.1207 |
| 84146 | ZNF644 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.96e-09 | -6.40e-01 | -0.1526 |
| 84146 | ZNF644 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.35e-30 | -7.24e-01 | -0.1464 |
| 84146 | ZNF644 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.02e-27 | -6.87e-01 | -0.1001 |
| 84146 | ZNF644 | HTA11_1391_2000001011 | Human | Colorectum | AD | 4.04e-09 | -5.38e-01 | -0.059 |
| 84146 | ZNF644 | HTA11_2992_2000001011 | Human | Colorectum | SER | 6.20e-05 | -8.06e-01 | -0.1706 |
| 84146 | ZNF644 | HTA11_5212_2000001011 | Human | Colorectum | AD | 4.30e-06 | -8.17e-01 | -0.2061 |
| 84146 | ZNF644 | HTA11_5216_2000001011 | Human | Colorectum | SER | 1.53e-04 | -8.88e-01 | -0.1462 |
| 84146 | ZNF644 | HTA11_546_2000001011 | Human | Colorectum | AD | 1.72e-02 | -6.09e-01 | -0.0842 |
| 84146 | ZNF644 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.55e-20 | -7.79e-01 | 0.096 |
| 84146 | ZNF644 | HTA11_4255_2000001011 | Human | Colorectum | SER | 2.23e-03 | -6.99e-01 | 0.0446 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF644 | SNV | Missense_Mutation | c.1395N>T | p.Lys465Asn | p.K465N | Q9H582 | protein_coding | deleterious(0.05) | probably_damaging(0.998) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| ZNF644 | SNV | Missense_Mutation | rs762203090 | c.212N>T | p.Thr71Met | p.T71M | Q9H582 | protein_coding | deleterious(0) | benign(0.333) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
| ZNF644 | SNV | Missense_Mutation | c.3463G>A | p.Glu1155Lys | p.E1155K | Q9H582 | protein_coding | tolerated(0.15) | benign(0.007) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ZNF644 | SNV | Missense_Mutation | c.2344N>G | p.His782Asp | p.H782D | Q9H582 | protein_coding | tolerated(0.13) | benign(0) | TCGA-AO-A0JC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD | |
| ZNF644 | SNV | Missense_Mutation | c.256G>A | p.Ala86Thr | p.A86T | Q9H582 | protein_coding | deleterious(0.03) | probably_damaging(0.978) | TCGA-BH-A0BG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF644 | SNV | Missense_Mutation | novel | c.2217G>T | p.Leu739Phe | p.L739F | Q9H582 | protein_coding | tolerated(0.15) | benign(0.001) | TCGA-BH-A8FZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZNF644 | SNV | Missense_Mutation | c.3787N>A | p.Cys1263Ser | p.C1263S | Q9H582 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-D8-A1JL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF644 | SNV | Missense_Mutation | c.2393N>G | p.Glu798Gly | p.E798G | Q9H582 | protein_coding | tolerated_low_confidence(0.13) | benign(0.001) | TCGA-GM-A2DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR | |
| ZNF644 | insertion | Nonsense_Mutation | novel | c.1218_1219insACTCTGTAGTAGGATCATCCAAAAAATCAGCT | p.Pro407ThrfsTer3 | p.P407Tfs*3 | Q9H582 | protein_coding | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| ZNF644 | insertion | Nonsense_Mutation | novel | c.978_979insTGTATTGGCAAATAATGTGGCAGATAAAGTAGCCAAAA | p.Glu327CysfsTer5 | p.E327Cfs*5 | Q9H582 | protein_coding | TCGA-A8-A091-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |